Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) have received a consensus recommendation of “Hold” from the ten brokerages that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $9.33.
Several equities analysts recently weighed in on the company. Royal Bank of Canada downgraded Fulcrum Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their price objective for the company from $15.00 to $4.00 in a research note on Thursday, September 12th. Leerink Partners reaffirmed a “market perform” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a research note on Thursday, September 12th. Bank of America cut Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and cut their price target for the stock from $10.00 to $2.00 in a report on Thursday, September 12th. Stifel Nicolaus lowered shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and reduced their target price for the company from $22.00 to $3.00 in a report on Thursday, September 12th. Finally, HC Wainwright lowered shares of Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the company from $17.00 to $4.00 in a research report on Friday, September 13th.
View Our Latest Stock Report on Fulcrum Therapeutics
Hedge Funds Weigh In On Fulcrum Therapeutics
Fulcrum Therapeutics Stock Performance
NASDAQ:FULC opened at $3.19 on Friday. Fulcrum Therapeutics has a 1 year low of $2.87 and a 1 year high of $13.70. The stock has a fifty day moving average price of $5.41 and a two-hundred day moving average price of $6.90. The stock has a market capitalization of $198.27 million, a price-to-earnings ratio of -1.99 and a beta of 2.21.
Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.87 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.93. The company had revenue of $80.00 million during the quarter, compared to analyst estimates of $80.00 million. During the same quarter last year, the business earned ($0.38) EPS. On average, analysts predict that Fulcrum Therapeutics will post -0.28 EPS for the current year.
Fulcrum Therapeutics Company Profile
Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.
Further Reading
- Five stocks we like better than Fulcrum Therapeutics
- How to Buy Cheap Stocks Step by Step
- MarketBeat Week in Review – 10/21- 10/25
- Health Care Stocks Explained: Why You Might Want to Invest
- Texas Roadhouse Stock Steering for New Highs This Year
- The Most Important Warren Buffett Stock for Investors: His Own
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.